Lupin has completed acquisition of 100% equity stake in Laboratorios Grin, S.A. De C.V., Mexico (Lab Grin) on September 30, 2014. Consequent to which, Lab Grin has become a wholly-owned subsidiary of the company with effect from September 30, 2014.
This acquisition marks the pharma major’s foray into the high growth Mexican and the larger Latin American pharmaceuticals market. Mexico is one of the fastest growing pharmaceutical markets in the world valued at over $13.5 billion and growing at 9-10% annually.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
